All Posts Tagged With: "BMY"
(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion
Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology...
(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies
Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated...
(API) Roche Holdings Partners with Evotec
Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover protein-phosphorylations,...
(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE:...
(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap
Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys...
(BMY) Bristol-Myers Squibb Compan Gets Good News
Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(AIG) Company News for May 12, 2011 – Corporate Summary
• Shares of Ener1, Inc. (NASDAQ:HEV) plunged by 27.35%, after the company reported a large first-quarter net loss this week. Ener1 Inc. was also downgraded by Wunderlich Securities from “Hold” to “Sell”...
(ISIS) Isis Pharmaceuticals Reported Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents.
Revenues...
(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing...
(MRK) Merck’s Cancer Drug Earns US Food and Drug Administration Clearance
Recently, the US Food and Drug Administration (FDA) cleared Merck & Co., Inc.’s (MRK) skin cancer (melanoma) drug, Sylatron (peginterferon alfa-2b). The once-weekly injectable drug has been approved...
(AMGN) Amgen Appeals EU Drug Opinion
Amgen (AMGN) is appealing the negative recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) for the use of Vectibix plus chemotherapy in patients with wild-type KRAS metastatic...
(BMY) Bristol-Myers Squibb Earns European Clearance for Baraclude
Recently, Bristol-Myers Squibb Company (BMY) received a boost with the European Commission (EC) approving Baraclude (entecavir) for an additional indication.
The current approval by the European regulatory...
(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
(SNY) Sanofi-Aventis Earnings Meet Expectations – Decrease From Year-Ago
Sanofi-Aventis (SNY) reported fourth quarter earnings of 96 cents per American Depository Share (ADS), a penny above the Zacks Consensus Estimate but below the year-ago earnings of $1.04. Full year earnings...
(AMZN) Company News for January 28, 2011 – Corporate Summary
• Microsoft (NASDAQ:MSFT) reported Q2 EPS of $0.77, above the Zacks Consensus Estimate of $0.55 per share. Revenues for the quarter were $19.95 billion, well above the Zacks Consensus Estimate of $16.073 billion
• Amazon.com...
(AZN) AstraZeneca Announces Response to FDA Complete Response Letter
AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided...
(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab
AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease.
The...
(AZN) AstraZeneca Suffers FDA Regulatory Setback
AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the...
(JNJ) Bayer and Johnson & Johnson Blood Thinner Xarelto Performs Well
Germany’s Bayer (BAYRY) received a huge boost when its blood thinner Xarelto (rivaroxaban), co-developed with Johnson & Johnson (JNJ),...
(PFE) Pfizer and Bristol-Myers Squibb Reports Another Pipeline Setback
Pfizer (PFE) and partner Bristol-Myers Squibb (BMY) recently suffered a setback with the development of their anti-clotting candidate, apixaban....
(BMY) Bristol-Myers Squibb Earns FDA Label Expansion
Recently, Bristol-Myers Squibb Co. (BMY) received a boost with the US Food and Drug Administration (FDA) approving Baraclude (entecavir) for an additional indication. The current approval by the US regulatory...
(KG) King Pharmaceuticals Quarterly Earnings Report Disappoints
In a filing with the US Securities and Exchange Commission (SEC), King Pharmaceuticals Inc. (KG) reported third-quarter earnings of 16 cents per share, a penny below the year-ago earnings. The Zacks Consensus...
(ISIS) Isis Pharmaceuticals Reports Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses.
However,...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(DD) September 2010 U.S. Trade Deficit Improves a Bit
The Trade Deficit fell in September to $44.00 billion after it rose in August to $46.48 billion. The fall in the trade deficit is very good news for the economy. The trade deficit was also smaller than the $44.8 billion consensus expectation. On a year-over-year...
(BMY) Bristol-Myers Squibb Beats Expectations on EPS – Misses on Sales
Bristol-Myers Squibb Company’s (BMY) third quarter 2010 earnings (excluding special items) of $0.59 per share surpassed the Zacks Consensus Estimate by $0.06. The company had earned $0.47 per share in the...
(BMY) Bristol-Myers Squibb’s Pipeline Advances
Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind,...
(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data
Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group,...
(ACHN) Achillion Pharmaceuticals’ Pipeline Makes Progress
Recently, Achillion Pharmaceuticals, Inc. (ACHN) announced that it has started dosing patients in a randomized, double-blind mid-stage study (n~120) that will evaluate pipeline candidate ACH-1625. The candidate...